HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Rose Sheet

You may also be interested in...



With Kalina Acquisition, Unilever Becomes Skin-Care Leader In Russia

Unilever’s acquisition of Ekaterinburg, Russia-based Concern Kalina will bolster the firm’s personal-care positioning in Russia, making it one of the market leaders in a locale where it previously struggled.

Arden Gives Facelift To Flagship Brand, Eyes Markets Abroad

Elizabeth Arden is modernizing its namesake cosmetics and fragrance brand to better position the range for international growth, the New York-based company announces.

Analyst: Outsider Heidenreich Brings Fresh Perspective As Beiersdorf CEO

Beiersdorf AG’s surprise move to name Stefan F. Heidenreich CEO in place of Thomas-B. Quaas will give the firm a competitive boost, according to analyst Andrew Wood of Bernstein Research.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS017838

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel